The answer depends on whether you mean a historical drug product or the compounded preparation offered today. Sermorelin was marketed in GEREF products with specific diagnostic and pediatric uses. Those products were later discontinued.
FDA determined in 2013 that the historical GEREF products were not withdrawn for safety or effectiveness reasons. That finding does not grant approval to a current compounded vial, a different formulation, or adult anti-aging claims.
Historical approval belongs to specific products and uses. Today’s compounded sermorelin is not an FDA-approved finished medicine.
What the 2013 determination actually addressed
The Federal Register notice concerned discontinued GEREF presentations and whether withdrawal was for safety or effectiveness reasons. It was a regulatory finding about those products, not a blanket statement that every future sermorelin preparation is approved.
When a provider cites the history, ask which current product is being prescribed and what status applies to it. An ingredient can have a history in an approved drug while a newly compounded preparation containing that ingredient remains unapproved.
Compounding and generic approval are different
FDA explains that compounded drugs are not FDA-approved and do not undergo its premarket review for safety, effectiveness, and quality. An FDA-approved generic follows a different approval process. Calling a compound a generic alternative can therefore create the wrong impression.
Compounding can serve a medical need when an approved product cannot meet an individual patient’s needs. That role does not erase the additional quality and evidence questions. Ask the clinician why the proposed preparation is appropriate for the particular patient.
Registration and licensing do not approve a drug
A pharmacy license identifies a regulatory authorization to operate within its scope. FDA facility registration, where relevant, is another kind of status. Neither phrase means every compounded product prepared there is FDA-approved.
Ask for the pharmacy’s name and verify the relevant licenses. Then ask for product-specific information: ingredients, concentration, quantity, beyond-use date, and directions. These checks answer practical questions that a broad “FDA-registered” statement does not.
What to ask when a sales page is unclear
Ask directly: Is this a compounded medicine? Has this exact finished product been FDA-approved for this use? Which pharmacy prepares it? What evidence supports the intended outcome? A provider should be able to answer without relying only on the history of GEREF.
Read the pharmacy verification guide and provider reviews together. The regulatory status is one part of an informed decision, alongside clinical suitability, evidence, cost, and the ability to obtain follow-up care.
Sources behind this article
Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.
- FDA: 2013 GEREF withdrawal determinationFederal Register / FDA · Historical GEREF products were not withdrawn for safety or effectiveness reasons; this does not approve current compounds.
- FDA: Risks of compounded drugsUS regulator · Explains lack of FDA approval and the risks of poor-quality compounded preparations.
- FDA: Compounding questions and answersUS regulator · Compounded medicines differ from FDA-approved generic drugs.